Beta Drugs raises Rs 117 cr from HealthQuad and others

Beta Drugs a vertically integrated oncology-focused formulations company, has raised primary capital worth Rs 117 crore from HealthQuad Fund II, and other investors including a Singapore-based investment fund and a private wealth management firm for a minority stake in the company.

Beta Drugs offers a broad product portfolio across major oncology segments, including chemotherapy, targeted, hormonal and supportive therapy. Beta Drugs has expanded its footprint to over 46 countries, holding accreditations from regulatory bodies such as ANVISA Brazil, INVIMA, PICS, and EAEU. The company was also honoured with the Forbes “Best Under a Billion” award in 2024.

Credit Source: ExpressPharma